证券日报网讯2月5日，科华生物（002022）在互动平台回答投资者提问时表示，面对行业政策与市场环 境的双重挑战，公司将坚守"全而精""融合创新"战略定位，以国民健康需求为核心导向，多措并举推动 企业稳健发展：(1)强化研销协同，挖掘增长新动能。公司持续保持研发投入，研发端聚焦多方法学技 术突破，构建覆盖全场景的整体解决方案，不断增强公司核心竞争力；营销端持续完善国内外销售与服 务网络，加速拓展海外市场，提升产品国际市场渗透率，培育新的业绩增长曲线。(2)深化精益管理， 推进数智化升级。公司将持续推进全价值链降本增效，通过精益管理优化资源配置效率，推动经营管理 数智化转型，充分释放提质增效潜力，提升整体运营效能，筑牢高质量发展根基。 ...

Group 1: Financial Performance and Challenges - The company reported a net profit loss of 2.34 billion in the past year, which increased to 6.41 billion in the current year, indicating a significant financial struggle [4][6]. - The company's overseas business accounts for 23% of its total revenue, with the U.S. market being a minor contributor [3][4]. - The asset-liability ratio stands at 24.22%, with cash reserves of approximately 787 million [4]. Group 2: Strategic Initiatives and Future Plans - The company aims to enhance operational efficiency through lean management and continuous improvement in quality and efficiency [2][3]. - Plans for 2025 include integrating global resources, advancing automation and digitalization, and expanding into diverse overseas markets [5][10]. - The company is committed to ongoing R&D investments to develop comprehensive solutions that meet national health needs [3][5]. Group 3: Market Position and Competitive Landscape - The company has a market coverage of approximately 60% in tertiary hospitals and 40% in blood stations within China [5]. - The company is focusing on enhancing its core products and expanding its market share through strategic marketing and product innovation [5][7]. - The competitive environment has intensified, leading to price reductions in various diagnostic product segments since 2022 [7]. Group 4: Governance and Management Concerns - There are concerns regarding the complexity of financial management due to multiple subsidiaries, which may lead to increased operational costs [6][8]. - The company has established a robust internal control system to ensure compliance and transparency in its operations [4][12]. - The management's compensation has reportedly increased despite the company's financial losses, raising questions about alignment with shareholder interests [6][7].